

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

CHANGE IN COMPOSITION OF THE BOARD AND ITS COMMITTEES

RETIREMENT OF CHIEF EXECUTIVE

IVD Medical Holding Limited (the “**Company**”) announces that Mr. Ho Kuk Sing has notified the board (the “**Board**”) of directors (the “**Directors**”) of the Company of his plan of retirement. He will retire as the chairman of the Board, an executive Director and the chief executive officer with effect from 1 July 2025. He will also cease to be the chairman of the nomination committee of the Company with effect from the same date. Mr. Ho will stay with the Company as a consultant.

Mr. Ho has confirmed that he has no disagreement with the Board, and there are no matters relating to his retirement that need to be brought to the attention of the shareholders of the Company or to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Company has begun a formal process to find a successor, considering both internal and external candidates. Mr. Ho will stay with the Company as a consultant for an orderly transition.

The Company thanked Mr. Ho for his leadership and for his contribution to the Group.

APPOINTMENT OF INEDS

The Company is pleased to announce the appointment of Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei as new independent non-executive Directors (“**INEDs**”), effective from 1 July 2025. Ms. Tai will also become the chairman of the nomination committee (the “**Nomination Committee**”) and a member of the audit committee (the “**Audit Committee**”) of the Company, and each of Mr. Xu and Mr. Zhang will also become a member of the Audit Committee and a member of the Nomination Committee with effect from the same date.

Biography of the new INEDs is set out below:

Ms. TAI Yang (邵洋), aged 30, graduated from Beijing Foreign Studies University with a bachelor's degree in management in July 2016. She was conferred a master's degree in engineering management by the Peking University in July 2024. She was designated a Certified Management Accountant by the Institute of Certified Management of the Institute of Management Accountants of the United States of America in March 2022. She was previously a non-practising member of The Chinese Institute of Certified Public Accountants, which was conferred to her in January 2023.

Mr. Tai has been a director of Zdeer Health Pte. Ltd. since August 2024. She is a partner of Wuhan Zdeer Xincheng Technology Partnership (Limited Partnership) and an executive director of Zdeer Health Technology (Henan) Co., Ltd.. Her other working experiences in the past include: the secretary to the board of directors and a finance responsible person of Zdeer Health Industry (Shenzhen) Co., Ltd., the secretary to the board of directors of Zdeer Industry (Hubei) Co., Ltd., a senior consultant of the advisory department of Ernst & Young (China) Advisory Limited Beijing Branch from March 2018 to October 2019, and worked in PWC International Assignment Services (Shanghai) Ltd. from November 2016 to February 2018.

Mr. XU Da (徐達), aged 54, graduated from Jilin University of Arts in December 2017 through self-taught higher education examinations.

Mr. Xu joined Tianjin Binhai Zhenxin Asset Management Co., Ltd. in 2019, and is now an investment director of such company.

Mr. ZHANG Jianlei (張建磊), aged 43, obtained a Bachelor of Economics from Peking University in June 2004. He is currently a member of the Chinese Institute of Certified Public Accountants. He was a non-practising member of the Beijing Institute of Certified Public Accountants, which was conferred to him in June 2011. He was conferred the qualification of a Public Valuer by the China Appraisal Society in September 2018 and he obtained the intermediate qualification level of financial and economics specialty approved by the Ministry of Human Resources and Social Security in China in November 2010.

Mr. Zhang has been a finance consultant of Beijing Kaili Gold Technology Co., Ltd. (北京凱利金科技有限公司) since September 2024. He joined Zhong De Securities Company Limited in December 2017, and his job title rank was director of internet and information technology industry department when he left in September 2024. His other working experiences in the past include: working in Huatai United Securities Co., Ltd.; working in the investment banking committee of Zhongtai Securities Company Limited from March 2011 to December 2017; working in Jianghai Securities Co., Ltd.; and working in BOC International Securities Co., Ltd..

In accordance with the Company's Articles of Association, each of the new INEDs will hold office as a Director until the annual general meeting to be held in 2026 (and be eligible for re-election). Each of them will enter into a letter of appointment with the Company for a term commencing on 1 July 2025 and expiring on the date of the annual general meeting at which she will retire.

Each of the new INEDs is entitled to receive a Director's fee determined by the Board, which is currently fixed at HK\$30,000, HK\$2,500 and HK\$5,000 per month for Ms. Tai, Mr. Xu and Mr. Zhang, respectively, pursuant to their respective letter of appointment. They are also eligible to receive other benefits and allowances under such letter of appointment, and participate in the provident fund (if applicable). Each of the new INEDs' remuneration was recommended

by the remuneration committee of the Company and approved by the Board in accordance with the Company's remuneration policy for Directors, with reference to individual role and duties, experience, responsibilities and comparable market practices.

Each of the new INEDs has confirmed: (i) his/her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he/she has no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his/her independence at the time of appointment.

Each of the new INEDs has also confirmed that, save as disclosed in this announcement, as of the date of this announcement, (i) he/she does not have any relationship with any of the Company's Directors, senior management, or substantial or controlling shareholders (as defined under the Listing Rules); (ii) he/she has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the preceding three years; (iii) he/she does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance; and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. The Company is not aware of any other matters relation to the appointment of the new INEDs that need to be brought to the attention of the shareholders of the Company.

Each of the new INEDs has obtained the legal advice referred to in Rule 3.09D of the Listing Rules on 30 June 2025, and each of them has confirmed that he/she understood his/her obligations as a director of a listed issuer on the same date.

The Board welcome the new INEDs to the Board.

By order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 30 June 2025

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Ho Kuk Sing, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Mr. Zhong Renqian, Dr. Leung Ka Sing and Dr. Wong Sze Lok.

In this announcement, certain Chinese names of institutions, natural persons or other entities have been translated into English and included as unofficial translations for identification purposes only. In the event of any inconsistency, the Chinese names shall prevail.